[ad_1]
The clinical trial of a coronavirus drug developed by Gedeon Richter Plc. It was approved by the National Institute of Pharmacy and Food Health. Therefore, the agent containing the antiviral agent remdesivir may be widely available to Hungarian patients.
Remdesivir is the most effective drug known to date against COVID-19.
In the first round, the product will be used by four higher education institutions with medical faculties, the University of Szeged, the University of Semmelweis, the University of Debrecen and the University of Pécs, as well as the South Pest Central Hospital, the National Institute of Early Pulmonology and New St. John’s Hospital. For the product to be widely used in Hungary, it still has to go through clinical phases.
The drug can be administered to patients treated at the above institutions who are 12 years of age or older and have a moderate to severe course of viral infection. The drug to be administered by infusion must be used as a cure, the therapy lasts for 5 to 10 days and can only be administered in health centers and will not be marketed to the general public. According to research to date, the drug is extremely effective against coronavirus: According to international data, it can reduce the risk of death by up to 50 percent, which is a very significant result.
In addition to Richter Gedeon Nyrt., ITM and EMMI grassroots institutions, operational staff, OGYÉI Clinical Pharmacology Ethics Committee and ETT all played an important role in the development of the drug and its delivery to patients. The main research coordinator is the Hungarian Clinical Research Infrastructure Network (HECRIN).
[ad_2]
